Spots Global Cancer Trial Database for Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemia
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemia
Official Title: A Phase 2, Open-label, Randomized Study to Evaluate the Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemia
Study ID: NCT01998828
Interventions
Study Description
Brief Summary: This open-label study is to determine the safety and efficacy of momelotinib in participants with either polycythemia vera (PV) or essential thrombocythemia (ET) who have not yet received treatment with a Janus kinase (JAK) inhibitor.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
, Scottsdale, Arizona, United States
, Whittier, California, United States
, Tupelo, Mississippi, United States
, Saint Louis, Missouri, United States
, Houston, Texas, United States
, Frankston, Victoria, Australia
, Parkville, Victoria, Australia
, Vancouver, British Columbia, Canada
, Toronto, Ontario, Canada
, Montreal, Quebec, Canada
, La Tronche, , France
, Nantes Cedex 1, , France
, Paris, , France
, Dresden, , Germany
, Minden, , Germany
Contact Details
Name: Peter Lee, MD, PhD
Affiliation: Gilead Sciences
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
